Drs Jeanny B. Aragon-Ching and Srikala Sridhar review key updates in the management of urothelial carcinoma from data presented in 2022.
EP. 1: Incidence and Risk Factors for Urothelial Carcinoma
Jeanny B. Aragon-Ching, MD, FACP, provides an overview of urothelial cancers and the process of diagnosis.
EP. 2: Neoadjuvant Chemotherapy as Standard-of-Care for Muscle-Invasive Urothelial Carcinoma
Srikala Sridhar, MD, MSc, FRCPC, explains the importance of neoadjuvant cisplatin-based chemotherapy and why bladder-sparing treatments should be considered for all patient populations.
EP. 3: Neoadjuvant Chemotherapy in Urothelial Carcinoma: The CHECKMATE-274 Trial
Experts discuss trial data from CHECKMATE-274 on the use of neoadjuvant chemotherapy for high-risk urothelial carcinoma treatment.
EP. 4: Neoadjuvant Chemotherapy in Urothelial Carcinoma: The IMvigor010 Study
Dr Jeanny B. Aragon-Ching starts a conversation on negative trial data in the high-risk urothelial carcinoma treatment setting for neoadjuvant chemotherapy.
EP. 5: Treatment Options for Frontline Metastatic Urothelial Carcinoma
Drs Aragon-Ching and Sridhar review the available treatment options for patients with frontline metastatic urothelial carcinoma and explain the design of an exciting clinical trial.
EP. 6: Outcomes of the JAVELIN Bladder 100 Trial
Jeanny B. Aragon-Ching, MD, FACP, describes the outcomes of the JAVELIN Bladder 100 study that she presented at ESMO 2022.
EP. 7: Metastatic Urothelial Carcinoma Treatment after Disease Progression on Avelumab
Key opinion leaders discuss the best treatment approaches for urothelial carcinoma after avelumab failure.
EP. 8: Key Trial Data in Urothelial Carcinoma Treatment from ESMO 2022
Srikala Sridhar, MD, MSc, FRCPC, and Jeanny B. Aragon-Ching, MD, FACP, wrap up their review of updates in urothelial carcinoma by highlighting exciting data presented at ESMO 2022.
Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma